Tag
Jagsonpal Pharmaceuticals Limited
2 articles
Jagsonpal Pharmaceuticals FY26 Results: Dividend, Buyback, Acquisition
Jagsonpal Pharmaceuticals reported FY26 revenue growth of 6.9% to ₹2,872 million with 19% PAT growth to ₹446 million, maintaining strong liquidity position.
The company declared ₹4 per share dividend
Jagsonpal Sends Physical AGM Notice Letters
Jagsonpal Pharmaceuticals issued physical letters to shareholders without registered email addresses to comply with SEBI LODR Regulation 36(1)(b).
The letters provide a web-link (https://www.jagsonpal